Periodic Reporting for period 1 - Sensa (Effortlessly Diagnosing Sleep Apnea with the Sensa Platform)
Reporting period: 2018-04-01 to 2018-09-30
Understanding and improving sleep is one of the most important medical, technological and societal challenges of our time. Sleep has, for decades, been perceived as an indulgence that should be minimized wherever and whenever possible. We are sleeping less than we were 40 years ago and this trend has started to backfire. The Centers for Disease Control and Prevention (CDC) in the United States has declared insufficient sleep a ‘public health problem’. According another study, more than a third of adults are not getting enough sleep on a regular basis.
The adverse effects of poor sleep quality on health, well-being and productivity have far-reaching societal and economic consequences. RAND Europe recently published a report analyzing the economic costs of insufficient sleep across Japan, Germany, UK, Canada and the USA. The conclusion is alarming: up to $680 billion is lost each year across the five countries due to insufficient sleep and poor sleep quality. A recent survey in Australia estimated also the overall financial and non-financial cost of inadequate sleep is $45.21 billion every year, or $1,822 per inhabitant. The researchers argue that these costs warrant substantial investment in preventive health measures to address the issue through education and regulation.
It is therefore a matter of public health to tackle with this issue, as well as an unprecedented economic opportunity.
The adverse effects of poor sleep quality on health, well-being and productivity have far-reaching societal and economic consequences. RAND Europe recently published a report analyzing the economic costs of insufficient sleep across Japan, Germany, UK, Canada and the USA. The conclusion is alarming: up to $680 billion is lost each year across the five countries due to insufficient sleep and poor sleep quality. A recent survey in Australia estimated also the overall financial and non-financial cost of inadequate sleep is $45.21 billion every year, or $1,822 per inhabitant. The researchers argue that these costs warrant substantial investment in preventive health measures to address the issue through education and regulation.
It is therefore a matter of public health to tackle with this issue, as well as an unprecedented economic opportunity.
To address this challenge, Neoma Labs has developed Sensa: a cost-effective, miniaturized and connected device that has the potential to become the reference end-to-end digitally-enabled automated solution for sleep diagnostic in Europe and across the globe. Scalable and easy to set up, the device provides the level of information healthcare professionals are used to review after hospital-based laboratory sleep tests.
This unique sensor measures mandibular movements using proprietary miniaturized AI-powered technology. Unlike many companies on the sleep market, Sensa will also be medical-grade certified (CE marked, class 2a). Validated on 500 subjects, the Sensa algorithms present best-in-class level of precision when compared against gold-standard polysomnography.
Importantly, Sensa offers also evolutive personalized recommendations for a better sleep to each and every user as well as, when necessary, therapeutic solutions best suited to the user’s individual sleep patterns. This technology is designed to help in a profound way the 30% people around the globe complaining about their sleep.
Sensa brings together the best of both worlds, with excellent balance between user-friendliness and diagnostic performance for clinicians.
The Belgium-based company Neoma Labs is currently looking for investors to develop sustained growth.
This unique sensor measures mandibular movements using proprietary miniaturized AI-powered technology. Unlike many companies on the sleep market, Sensa will also be medical-grade certified (CE marked, class 2a). Validated on 500 subjects, the Sensa algorithms present best-in-class level of precision when compared against gold-standard polysomnography.
Importantly, Sensa offers also evolutive personalized recommendations for a better sleep to each and every user as well as, when necessary, therapeutic solutions best suited to the user’s individual sleep patterns. This technology is designed to help in a profound way the 30% people around the globe complaining about their sleep.
Sensa brings together the best of both worlds, with excellent balance between user-friendliness and diagnostic performance for clinicians.
The Belgium-based company Neoma Labs is currently looking for investors to develop sustained growth.
To address this challenge, Neoma Labs has developed Sensa: a cost-effective, miniaturized and connected device that has the potential to become the reference end-to-end digitally-enabled automated solution for sleep diagnostic in Europe and across the globe. Scalable and easy to set up, the device provides the level of information healthcare professionals are used to review after hospital-based laboratory sleep tests.
This unique sensor measures mandibular movements using proprietary miniaturized AI-powered technology. Unlike many companies on the sleep market, Sensa will also be medical-grade certified (CE marked, class 2a). Validated on 500 subjects, the Sensa algorithms present best-in-class level of precision when compared against gold-standard polysomnography.
Importantly, Sensa offers also evolutive personalized recommendations for a better sleep to each and every user as well as, when necessary, therapeutic solutions best suited to the user’s individual sleep patterns. This technology is designed to help in a profound way the 30% people around the globe complaining about their sleep.
Sensa brings together the best of both worlds, with excellent balance between user-friendliness and diagnostic performance for clinicians.
The Belgium-based company Neoma Labs is currently looking for investors to develop sustained growth.
This unique sensor measures mandibular movements using proprietary miniaturized AI-powered technology. Unlike many companies on the sleep market, Sensa will also be medical-grade certified (CE marked, class 2a). Validated on 500 subjects, the Sensa algorithms present best-in-class level of precision when compared against gold-standard polysomnography.
Importantly, Sensa offers also evolutive personalized recommendations for a better sleep to each and every user as well as, when necessary, therapeutic solutions best suited to the user’s individual sleep patterns. This technology is designed to help in a profound way the 30% people around the globe complaining about their sleep.
Sensa brings together the best of both worlds, with excellent balance between user-friendliness and diagnostic performance for clinicians.
The Belgium-based company Neoma Labs is currently looking for investors to develop sustained growth.